Puma Biotechnology has launched a Phase II study for Alisertib, targeting Small Cell Lung Cancer, named ALISCA-Lung1.

Galderma declares submission approval of Nemolizumab for treating Prurigo Nodularis and Eczema in America and Europe.

Biogen Secures European Commission for New Drug SKYCLARYS® (omaveloxolone), Pioneering Treatment for Friedreich’s Ataxia.

CSL Reveals Key Findings of Phase 3 AEGIS-II Study Assessing Effectiveness and Security of CSL112 (Human Apolipoprotein A-I).

Adverum Biotech Reports Encouraging Initial Results for Safety and Effectiveness in Phase 2 LUNA Study of Ixo-vec for Wet Age-Related Macular Degeneration Patients.

At the EAHAD Congress in 2024, Hemab Therapeutics Unveils Encouraging Initial Findings for Their Drug, HMB-001, Targeting Glanzmann's Thrombasthenia.

Chugai Pharmaceutical announced that China's National Medical Products Administration approved its innovative C5 monoclonal antibody, crovalimab.

In a Phase 2b clinical trial, the experimental oral peptide known as JNJ-2113 has shown encouraging outcomes for patients with moderate to severe psoriasis.

REGENXBIO Confirms Major Milestone Reached in Crucial Study of RGX-121 as Therapy for MPS II, Successfully Hitting Primary Goal.

Zymedi has begun first human trials of ZMA001, a novel monoclonal antibody for treating Pulmonary Arterial Hypertension.

Encoded Therapeutics Reveals Approval from US FDA for IND Application and Consent from Australian Health Authorities for ETX101, a Genetic Treatment Prospect for Dravet Syndrome.

Scholar Rock's Study Reveals SRK-439's Potential Influence on Muscle Mass and Metabolic Health in Weight Loss Efforts.